Bardy Diagnostics announced that it was selected as winner of the ‘Remote Monitoring in Arrhythmias’ Technology and Innovation Pitch Session held as part of the digital health programme at the European Society of Cardiology (ESC) Congress 2019 (31 August–4 September, Paris, France).
BardyDx earned the distinction for its Carnation Ambulatory Monitor (CAM), a P-wave centric ambulatory cardiac patch monitoring and arrhythmia detection device, the company said in a press release.
The pitch event was held on the Digital Health Stage as part of ESC’s focus on highlighting technological applications in the field of e-cardiology and how they are impacting research and clinical practice, including wearable devices, mobile apps, electronic health records, and big data. Over a dozen pitch session events provided selected applicants the opportunity to present on their digital health technology, including categories in artificial intelligence, m-health, wearables, and remote monitoring.
“It is an honour for the CAM patch to be chosen and recognized as one of the best remote cardiac monitoring solutions from among those presenting by an audience of pioneering cardiac physicians and industry thought leaders,” said Ken Nelson, BardyDx chief commercial officer and pitch session presenter. “We are committed to providing optimal P-wave focused digital health solutions that inform the modern-day cardiology practice.”
In addition, BardyDx founder and chief executive officer, Gust H Bardy, was invited to speak at Heart Rhythm Congress (HRC) 2019 (6–9 October, Birmingham, UK). As part of the AF Association Symposia’s ‘Management of Atrial Fibrillation’ session, Bardy’s presentation highlighted the significance of high-fidelity ECG tracings in accurate arrhythmia diagnosis and treatment decisions.
The CAM patch has experienced strong commercial demand due to its proprietary P-wave centric digital health platform, BardyDx said, which provides clinicians diagnostically-accurate data. Also, the CAM patch recently received 510(k) clearance by the US Food and Drug Administration (FDA) to extend monitoring duration up to 14 days.
